Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ruxoprubart - NovelMed Therapeutics

Next Previous
Drug Profile

Ruxoprubart - NovelMed Therapeutics

Alternative Names: Anti-Bb; NM-8074

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovelMed Therapeutics
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Complement C3-C5 convertases inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Paroxysmal nocturnal haemoglobinuria
  • Phase I Anti-neutrophil cytoplasmic antibody-associated vasculitis; Atypical Haemolytic Uraemic Syndrome; Dermatomyositis; IgA nephropathy; Membranoproliferative glomerulonephritis

Most Recent Events

  • 20 May 2025 Efficacy and adverse events data from a phase II trial in Paroxysmal nocturnal haemoglobinuria released by NovelMed Therapeutics
  • 25 Mar 2025 NovelMed Therapeutics plans a phase-II trial for Dermatomyositis in June 2026 (IV, Infusion), (NCT06887738)
  • 24 Feb 2025 US FDA approves IND application for efficacy phase II trial for Dermatomyositis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top